{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Hsiao CC"],"pubmed_abstract":["<b>Background:</b> Statins are commonly used for cardiovascular disease (CVD) prevention. Observational studies reported the effects on sepsis prevention and mortality improvement. Patients with chronic kidney disease (CKD) are at high risk for CVD and infectious diseases. Limited information is available for statin use in patients with non-dialysis CKD stage V. <b>Method:</b> The retrospective observational study included patients with non-dialysis CKD stage V, with either <i>de novo</i> statin use or none. Patients who were prior statin users and had prior cardiovascular events were excluded. The key outcomes were infection-related hospitalization, major adverse cardiovascular events (MACE) (non-fatal myocardial infarction, hospitalization for heart failure, or non-fatal stroke), and all"],"journal":["Frontiers in pharmacology"],"pagination":["996237"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9561676"],"repository":["biostudies-literature"],"pubmed_title":["Statin uses in adults with non-dialysis advanced chronic kidney disease: Focus on clinical outcomes of infectious and cardiovascular diseases."],"pmcid":["PMC9561676"],"pubmed_authors":["Chen JS","Hsiao CC","Li YR","Lin C","Chen KH","Sun WC","Yen CL","Fan PY","Yeh JK"],"additional_accession":[]},"is_claimable":false,"name":"Statin uses in adults with non-dialysis advanced chronic kidney disease: Focus on clinical outcomes of infectious and cardiovascular diseases.","description":"<b>Background:</b> Statins are commonly used for cardiovascular disease (CVD) prevention. Observational studies reported the effects on sepsis prevention and mortality improvement. Patients with chronic kidney disease (CKD) are at high risk for CVD and infectious diseases. Limited information is available for statin use in patients with non-dialysis CKD stage V. <b>Method:</b> The retrospective observational study included patients with non-dialysis CKD stage V, with either <i>de novo</i> statin use or none. Patients who were prior statin users and had prior cardiovascular events were excluded. The key outcomes were infection-related hospitalization, major adverse cardiovascular events (MACE) (non-fatal myocardial infarction, hospitalization for heart failure, or non-fatal stroke), and all","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T23:02:02.317Z","creation":"2025-04-04T23:02:02.317Z"},"accession":"S-EPMC9561676","cross_references":{"pubmed":["36249758"],"doi":["10.3389/fphar.2022.996237"]}}